Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Conclusions: Atezo plus dara and in combination with len or pom demonstrated acceptable tolerability; no new safety signals were identified. Some pts treated with either atezo plus dara or atezo plus dara and IMiD appeared to have deep and durable responses. The benefit-risk profile of atezo in combination with dara with/without pom in R/R MM pts is promising. These early data support continuation of the study.DisclosuresCho: Agenus Inc.: Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; J & J: Consultancy; BMS: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Genentech Inc: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Costa: BMS: Research Funding; Sanofi: Honoraria; Abbvie: Research Funding; Celgene: Honoraria, Research Funding; Janssen: Research Funding; Amgen: Honoraria, Research Funding; Karyopharm: Research Funding. Davies: Abbvie: Consultancy; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; MMRF: Honoraria; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; ASH: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; TRM Oncology: Honoraria. Vij: Bristol Myer Squibb: Honoraria, Research Fun...

Source: Blood - November 21, 2018 Category: Hematology Authors: Cho, H. J., Costa, L. J., Davies, F. E., Neparidze, N., Vij, R., Feng, Y., Teterina, A., Wassner Fritsch, E., Wenger, M., Kaufman, J. L. Tags: 653. Myeloma: Therapy, excluding Transplantation: Antibodies and Targeted Therapies Source Type: research